Full text is available at the source.
Abstract
Short-term tirzepatide therapy may be associated with changes in mean platelet volume in patients with obesity.
- Obesity is linked to chronic low-grade inflammation and cardiovascular risk.
- Mean platelet volume (MPV) serves as a surrogate marker for platelet activation and inflammation.
- The relationship between tirzepatide therapy and MPV changes has been evaluated in this context.
- An untreated control group was included for comparison.
Simplified